X4C

Executive Summary

X4C is a Belgian biotechnology company leveraging its proprietary calix[4]arene-based platform to enhance the coating of biomolecules (antibodies, proteins, peptides) on diverse surfaces. Founded in 2021 and based in Leuven, the technology aims to improve the performance and versatility of surface functionalization for applications in cell therapy and immunology. By enabling covalent or passive binding on any surface shape or dimension, X4C's approach could address key limitations in biomolecule immobilization, potentially accelerating the development of next-generation diagnostics, therapeutics, and cell-based treatments. The company is privately held and early-stage, with no disclosed funding or valuation, indicating a focus on technology validation and initial partnerships. X4C's platform is positioned to serve the growing demand for advanced surface coatings in bioprocessing and medical devices.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data in cell therapy applications60% success
• Q1 2027Strategic partnership with a biopharma or medical device company50% success
• Q2 2027Series A funding round completion45% success